75199-26-7

Upstream product

• 104-86-9 4-chlorobenzylamine 
• 3849-21-6 ethyl cyanoglyoxylate-2-oxime 

Downstream Products

• 75185-00-1 4-[(4-chlorophenyl)methyl]-6,7-dihydro-1,2,6-trimethyl-1H-imidazo[1,2-a]purin9(4H)-one 
• 75184-97-3 4-[(4-chlorophenyl)methyl]-6,7-dihydro-1,6-dimethyl-1H-imidazo[1,2-a]purin-9(4H)-one 
• 75199-28-9 4-<(4-chlorophenyl)methyl>-6,7-dihydro-6-methyl-3H-imidazo<1,2-a>purin-9(4H)-one 
• 75184-72-4 N-[7-Amino-8-(4-chloro-benzyl)-2-methyl-5-oxo-2,3,5,8-tetrahydro-imidazo[1,2-a]pyrimidin-6-yl]-formamide 

Relevant academic research and scientific papers

Substituted 6,7-dihydroimidazo[1,2-al]purin-9 (4H)-ones

The synthesis of a series of substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones is described. Several members of the series exhibit enhanced antiallergic and bronchodilator activity and reduced side effects as compared to theophylline. Structure-activity relationships and metabolic considerations are discussed for the series. Analogues substituted with a 4-(4-chlorobenzyl) moiety, such as 33 and 40, show an optimal balance of antiallergic and bronchodilator activity and are of particular interest. Compound 33 is significantly more potent than theophylline against both metacholine- and antigen-induced bronchospasms, does not affect spontaneous motor activity, and shows minimal cardiovascular effects in the rat.